-
Laboratoires Thea
- Business Development Manager
CLERMONT FERRAND
2019 - maintenant
- Scouting of innovative therapeutic solutions in Ophthalmology and Ocular Healthcare
- Négotiation of global partnering under in licensing-in and co-development with Mid-size Pharma, Biotechs and Start-ups
- Strategy and operational implementation of the deal structure
-
Triacor Conseils
- Consultant/Manager de transition
2017 - 2018
Management de Transition, Business Development IPSEN CHC, BoulogneBillancourt, France, 7 Mois
- scouting, in licensing, management de partenariats Rx, OTC, Food supplements en GI & Inflammation
- global alliance management de projets en GI en Chine
- management de projets en Food Supplements (Probiotics) en GI
Stratégie et conseils en Recherche & Développement pour des SMEs, start-ups, CROs en preclinical safety, dispositifs médicaux et outils diagnostics in vitro en cardiovasculaire et maladies neurodégénératrices
-
IDF INNOV
- Business Development Healthcare & Strategic partnerships
2015 - 2017
- Analyse stratégique des transferts de l’innovation académique des Universités d’ile de France et Paris par valorisation avec des partenariats industriels, CDMOs et associations des PMEs et ETIs
- Mise en place et gestion des contrats de transferts en start-ups, licences, collaborations et co-développements de petites molécules, protéines, vaccins, biomarqueurs et dispositifs médicaux en Immunologie, Oncologie CAR-T cells, Maladies rares et Neurodégénératrices, Gastroenterologie et Dermatologie
-
Independent
- Business Development Healthcare & Innovation
2014 - 2019
- Stratégie d'expansion d'accès aux marchés et partenariats (licensing, co-développement, alliances)
- Optimisation de la performance R&D pour une accélération d' accès aux marchés
- Leadership et encadrement d'équipes pour un centre R&D d'excellence
-
Sanofi Pasteur
- International Business Development Manager Commercial Operations
Lyon
2013 - 2014
- Public market access for emerging countries in particular:
Greater Europe: Russia for the pediatric vaccines, identification of local CDMOS and governmental partners,
Brazil for the influenza vaccines, R&D support for Regulatory filing with dedicated CDMOs
- Strategic analysis to increase our public market access performance rate, in coordination with the main corporate functions (industrial operations, supply chain, clinical and regulatory departments, financials and legal functions, marketing operations) and the local business units,
-
L'Oréal
- Business Unit Manager CDMO of SkinEthic
PARIS
2006 - 2012
CDMO affiliated company of L'Oréal group, 15FTEs, 3Mn EUR
- Board member of SkinEthic
- Operational and strategic management of the business unit dedicated to bioengineering of human skin and cornea as in vitro preclinical screening tools: investments into research "omics" based tools, optimization of the performance of the production lines (under sterile & GLP conditions) & of the communication kits and distribution networks, ISO 9001 certification
- European validation of epidermal in vitro models in replacement of the in vivo animal test for acute skin irritation
- Implementation of distribution networks in Japan and USA
-
Novartis Pharma AG
- Head of Alliance Management, Translational Medicine, Early Development
RUEIL MALMAISON
2000 - 2006
- Alliance management of industrial and academic partnerships in EU (preclinical and clinical CROs), USA (Organogenesis, biotechnologies), Asia (Clinical CROs in India) to support the market expansion
- Market access of innovative products, mainly, in Immunology: in Asthma, Inflammation, Oncology, Dermatology: cyclosporin, rapamycin, monoclonal antibodies (anti-IgE, anti-TNFalpha, anti-VEGF)
- Proof of concept strategies presented to Key Opinion Leaders and the Healthcare Authorities (FDA on tiered strategy on ``omics'' based biomarkers) in order to develop a personalized medicine
-
Novartis Pharma AG
- Senior Toxicologist, Research & development
RUEIL MALMAISON
1993 - 1999
- Management of technological platforms in Immunotoxicology (local tolerance and contact (photo) allergy) and Drug Delivery Systems (dermatological, transdermal, subcutaneous, nasal and pulmonary formulations) under GLP conditions
- Development of preclinical programs to support the launch of products in Immunology (Sandostatin, Neoral, Sandimmun, Certican), in Asthma (Xolair), in metabolic disease (Somatostatin) and in Dermatology (Elidel, Lamisil, Apligraf)
-
INSERM
- Research Fellowship UC Davis, CA, USA
PARIS 13
1989 - 1990
Research Fellow INSERM, Dermatology Dept Veterans Administration, Dr. B. Berman
Effects of pentoxyphilline on interferon gamma and tumor necrosis alpha induction of intercellular adhesion molecule (ICAM-1) expression on human normal keratinocytes and Langerhans cells. European Journal of Dermatology, 2, 4: 265-272, 1992.
-
Hospices Civils de Lyon
- Interne des HCL
Lyon
1985 - 1989
Interne en Recherche Dermatologie Pavillon R Hôpital Edouard Herriot, Lyon
